Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ensysce Biosciences (ENSC) Operating Expenses (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Operating Expenses for 6 consecutive years, with $4.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses rose 52.63% to $4.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $15.5 million, a 44.66% increase, with the full-year FY2024 number at $11.9 million, down 7.79% from a year prior.
  • Operating Expenses was $4.2 million for Q3 2025 at Ensysce Biosciences, up from $3.1 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $18.1 million in Q3 2021 to a low of $774849.0 in Q1 2021.
  • A 5-year average of $4.5 million and a median of $3.4 million in 2023 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: surged 1367.66% in 2021, then crashed 64.38% in 2022.
  • Ensysce Biosciences' Operating Expenses stood at $3.6 million in 2021, then soared by 109.61% to $7.6 million in 2022, then crashed by 51.92% to $3.7 million in 2023, then skyrocketed by 32.95% to $4.9 million in 2024, then fell by 13.24% to $4.2 million in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Operating Expenses are $4.2 million (Q3 2025), $3.1 million (Q2 2025), and $3.3 million (Q1 2025).